CIDEC Rabbit anti-Human, Mouse, Polyclonal, Invitrogen
Rabbit Polyclonal Antibody
Manufacturer: Invitrogen PA14316
PA1-4316 detects the human CIDE-3 protein in human samples. Expected to recognize mouse samples due to 93% sequence homology. PA1-4316 has been successfully used in Western blot procedures. By Western blot this antibody detects a ~27 kDa protein representing human CIDE-3 in HepG2 cell lysate. The PA1-4316 immunogen is a synthetic peptide corresponding to residues L(10) L Y P K S L S R H V S V R T S(25) of human CIDE-3. This antibody shows cross-reactivity to FSP27, which is the mouse homolog of CIDE-3, with a sequence identity of 93%. Maintain at 4°C for 3 months or at -20°C for longer periods. Avoid repeated freeze-thaw cycles.DNA fragmentation is one of the critical steps in apoptosis, which is induced by DNA fragmentation factor (DFF). DFF is composed of two subunits, a 40 kDa caspase-activated nuclease (DFF40) and a 45 kDa inhibitor (DFF45). Recently a novel family of cell-death-inducing DFF45-like effectors (CIDEs) has been identified. Human CIDE-3 is a novel member of CIDEs. There are 2 transcripts, CIDE-3 and CIDE-3alpha, were present in HepG2 and A375 cells. Consistent with its chromosome localization at 3p25, a region associated with high frequency loss of heterozygosity in many tumours, CIDE-3 may play an important role in prevention of tumorigenesis.
|Synthetic peptide corresponding to residues L(10) L Y P K S L S R H V S V R T S(25) of human CIDE-3.|
|Antigen affinity chromatography|
|PBS with 0.02% sodium azide|
|Cell death activator CIDE-3, Cell death-inducing DFFA-like effector protein C, Fat-specific protein FSP27 homolog|
|Maintain refrigerated at 2-8°C for up to 3 months. For long term storage store at -20°C|
We continue to work to improve your shopping experience and your feedback regarding this content is very important to us. Please use the form below to provide feedback related to the content on this product.
Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.Ok